Soleno Therapeutics, Inc. (SLNO) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
158.68
+10% vs avg
5yr avg: 144.29
P/FCF
59.06
+10% vs avg
5yr avg: 53.84
30Y Low53.8·High53.8
P/B Ratio
↓
6.39
-7% vs avg
5yr avg: 6.88
30Y Low3.0·High33.6
ROE
↑
6.0%
↓+108% vs avg
5yr avg: -79.3%
30Y Low-493%·High6%
Debt/EBITDA
0.16
+0% vs avg
5yr avg: 0.16
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SLNO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Soleno Therapeutics, Inc. trades at 135.8x earnings, 14% above its 5-year average of 118.7x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 508%. On a free-cash-flow basis, the stock trades at 59.1x P/FCF, 10% above the 5-year average of 53.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.8B | $2.5B | $1.8B | $664M | $83M | $164M | $604M | $502M | $179M | $81M | $63M |
| Enterprise Value | $2.7B | $2.4B | $1.8B | $495M | $69M | $143M | $555M | $481M | $156M | $64M | $60M |
| P/E Ratio → | 135.77 | 118.72 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.49 | 13.21 | — | — | — | — | — | — | — | — | 43.29 |
| P/B Ratio | 6.39 | 5.59 | 7.37 | 4.21 | 8.03 | 9.19 | 13.27 | 33.58 | 5.90 | 3.05 | 18.28 |
| P/FCF | 59.06 | 53.84 | — | — | — | — | — | — | — | — | — |
| P/OCF | 58.97 | 53.75 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SLNO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Soleno Therapeutics, Inc.'s enterprise value stands at 158.7x EBITDA, 10% above its 5-year average of 144.3x. The Healthcare sector median is 14.4x, placing the stock at a 1003% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.86 | — | — | — | — | — | — | — | — | 41.41 |
| EV / EBITDA | 158.68 | 144.29 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 180.09 | 92.85 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 52.39 | — | — | — | — | — | — | — | — | — |
SLNO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Soleno Therapeutics, Inc. earns an operating margin of 7.9%. ROE of 6.0% is modest. ROIC of 3.8% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.6% | 98.6% | — | — | — | — | — | — | — | 100.1% | -4.0% |
| Operating Margin | 7.9% | 7.9% | — | — | — | — | — | — | — | 0.8% | -938.1% |
| Net Profit Margin | 11.0% | 11.0% | — | — | — | — | — | — | — | 1.0% | -831.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 6.0% | 6.0% | -87.4% | -46.5% | -171.0% | -97.6% | -81.5% | -135.7% | -46.8% | -104.6% | -362.4% |
| ROA | 4.7% | 4.7% | -68.7% | -37.6% | -77.6% | -61.5% | -47.8% | -75.7% | -32.5% | -70.3% | -175.3% |
| ROIC | 3.8% | 3.8% | -142.0% | — | — | — | — | -1898.3% | -128.1% | -180.0% | -1439.3% |
| ROCE | 3.7% | 3.7% | -78.0% | -43.9% | -104.4% | -75.1% | -71.3% | -62.3% | -36.4% | -59.2% | -307.0% |
SLNO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Soleno Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.2x, which is very conservative (95% below the sector average of 3.3x). The company holds a net cash position — cash of $70M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 4.8x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.22 | 0.00 | 0.01 | 0.03 | 0.00 | 0.02 | — | — | — |
| Debt / EBITDA | 0.16 | 0.16 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.15 | -0.14 | -1.07 | -1.40 | -1.17 | -1.08 | -1.37 | -0.76 | -0.64 | -0.79 |
| Net Debt / EBITDA | -3.97 | -3.97 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -1.44 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 4.81 | 4.81 | -760.26 | — | — | — | — | — | -221.52 | — | — |
Net cash position: cash ($70M) exceeds total debt ($3M)
SLNO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Soleno Therapeutics, Inc.'s current ratio of 5.80x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 14.89x to 5.80x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.80 | 5.80 | 15.68 | 14.89 | 2.14 | 2.80 | 5.83 | 4.26 | 13.14 | 10.38 | 2.23 |
| Quick Ratio | 5.55 | 5.55 | 15.68 | 14.89 | 2.14 | 2.80 | 5.83 | 4.26 | 13.14 | 10.38 | 1.84 |
| Cash Ratio | 4.98 | 4.98 | 15.55 | 14.75 | 2.00 | 2.66 | 5.71 | 4.18 | 12.83 | 9.87 | 1.60 |
| Asset Turnover | — | 0.34 | — | — | — | — | — | — | — | -39.80 | 0.26 |
| Inventory Turnover | 0.18 | 0.18 | — | — | — | — | — | — | — | — | 2.29 |
| Days Sales Outstanding | — | 54.07 | — | — | — | — | — | — | — | — | 33.55 |
SLNO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Soleno Therapeutics, Inc. returns 3.6% to shareholders annually primarily through share buybacks. The earnings yield of 0.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.7% | 0.8% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.7% | 1.9% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 3.6% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 12.4% |
| Total Shareholder Yield | 3.6% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 12.4% |
| Shares Outstanding | — | $54M | $40M | $16M | $8M | $5M | $4M | $2M | $1M | $598519 | $206766 |
Peer Comparison
Compare SLNO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SLNOYou | $3B | 135.8 | 158.7 | 59.1 | 98.6% | 7.9% | 6.0% | 3.8% | 0.2 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 RYTM | $7B | -30.9 | — | — | 89.7% | -101.2% | -129.5% | -70.1% | — |
 MDGL | $12B | -41.6 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 ANAB | $3B | -145.6 | 52.9 | 147.2 | 99.0% | 20.4% | -24.5% | 55.1% | 0.3 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 LGND | $4B | -956.0 | 322.1 | 53.4 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See SLNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLNO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLNO vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonSLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
What is Soleno Therapeutics, Inc.'s P/E ratio?
Soleno Therapeutics, Inc.'s current P/E ratio is 135.8x. The historical average is 118.7x. This places it at the 100th percentile of its historical range.
What is Soleno Therapeutics, Inc.'s EV/EBITDA?
Soleno Therapeutics, Inc.'s current EV/EBITDA is 158.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Soleno Therapeutics, Inc.'s ROE?
Soleno Therapeutics, Inc.'s return on equity (ROE) is 6.0%. The historical average is -147.3%.
Is SLNO stock overvalued?
Based on historical data, Soleno Therapeutics, Inc. is trading at a P/E of 135.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Soleno Therapeutics, Inc.'s profit margins?
Soleno Therapeutics, Inc. has 98.6% gross margin and 7.9% operating margin.
How much debt does Soleno Therapeutics, Inc. have?
Soleno Therapeutics, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.